Evidence map›Paper›PMID 24751777›Full record

ArticlePloS one2014

Sub-inhibitory fosmidomycin exposures elicits oxidative stress in Salmonella enterica serovar Typhimurium LT2.

David T Fox, Emily N Schmidt, Hongzhao Tian, Suraj Dhungana, Michael C Valentine, Nicole V Warrington, Paul D Phillips, Kellan B Finney, Emily K Cope, Jeff G Leid and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

David T FoxBioscience Division, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Emily N SchmidtBioscience Division, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Hongzhao TianBioscience Division, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Suraj DhunganaBioscience Division, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Michael C ValentineDepartment of Biology, Northern Arizona University, Flagstaff, Arizona, United States of America.
Nicole V WarringtonDepartment of Chemistry, Northern Arizona University, Flagstaff, Arizona, United States of America.
Paul D PhillipsDepartment of Chemistry, Northern Arizona University, Flagstaff, Arizona, United States of America.
Kellan B FinneyDepartment of Chemistry, Northern Arizona University, Flagstaff, Arizona, United States of America.
Emily K CopeDepartment of Biology, Northern Arizona University, Flagstaff, Arizona, United States of America.
Jeff G LeidDepartment of Biology, Northern Arizona University, Flagstaff, Arizona, United States of America.
Charles A TestaEchelon Biosciences, Inc, Salt Lake City, Utah, United States of America.
Andrew T KoppischDepartment of Chemistry, Northern Arizona University, Flagstaff, Arizona, United States of America.
Northern Arizona University · USLos Alamos National Laboratory · USEchelon Biosciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fosmidomycin is a time-dependent nanomolar inhibitor of methylerythritol phosphate (MEP) synthase, which is the enzyme that catalyzes the first committed step in the MEP pathway to isoprenoids. Importantly, fosmidomycin is one of only a few MEP pathway-specific inhibitors that exhibits antimicrobial activity. Most inhibitors identified to date only exhibit activity against isolated pathway enzymes. The MEP pathway is the sole route to isoprenoids in many bacteria, yet has no human homologs. The development of inhibitors of this pathway holds promise as novel antimicrobial agents. Similarly, analyses of the bacterial response toward MEP pathway inhibitors provides valuable information toward the understanding of how emergent resistance may ultimately develop to this class of antibiotics. We have examined the transcriptional response of Salmonella enterica serovar typhimurium LT2 to sub-inhibitory concentrations of fosmidomycin via cDNA microarray and RT-PCR. Within the regulated genes identified by microarray were a number of genes encoding enzymes associated with the mediation of reactive oxygen species (ROS). Regulation of a panel of genes implicated in the response of cells to oxidative stress (including genes for catalases, superoxide dismutases, and alkylhydrogen peroxide reductases) was investigated and mild upregulation in some members was observed as a function of fosmidomycin exposure over time. The extent of regulation of these genes was similar to that observed for comparable exposures to kanamycin, but differed significantly from tetracycline. Furthermore, S. typhimurium exposed to sub-inhibitory concentrations of fosmidomycin displayed an increased sensitivity to exogenous H2O2 relative to either untreated controls or kanamycin-treated cells. Our results suggest that endogenous oxidative stress is one consequence of exposures to fosmidomycin, likely through the temporal depletion of intracellular isoprenoids themselves, rather than other mechanisms that have been proposed to facilitate ROS accumulation in bacteria (e.g. cell death processes or the ability of the antibiotic to redox cycle).

Indexed as

Anti-Bacterial AgentsBiosynthetic PathwaysFosfomycinGene Expression Regulation, BacterialHemiterpenesHumansHydrogen PeroxideKanamycinMicrobial Sensitivity TestsOligonucleotide Array Sequence AnalysisOrganophosphorus CompoundsOxidative StressSalmonella typhimuriumTime Factors3,3-dimethylallyl pyrophosphateAnti-Bacterial AgentsFosfomycinfosmidomycinHemiterpenesHydrogen Peroxideisopentenyl pyrophosphateKanamycinOrganophosphorus Compounds

Identifiers

PMID24751777
PMCPMC3994034
OpenAlexW2038262629

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.